Cue Biopharma (NASDAQ: CUE) has announced that Usman Azam, MD has been appointed president and CEO of Cue Biopharma, effective today. Daniel Passeri will transition from his current role as CEO to one of strategic advisor.
Dr. Azam brings more 25 years of drug discovery and development leadership as well as operating expertise to the role. Most recently, he served as CEO of closely held Inspirna, a clinical stage biopharmaceutical company focused on the discovery and development of novel cancer drugs.
In a statement, Daniel Passeri, CEO of Cue, commented, “This strategic transition in leadership is a timely and important step forward, enhancing the company’s next stage of corporate development with a prioritized focus on autoimmune disease. Dr. Azam‘s significant experience across the entire drug development value-chain, including clinical trial design and execution, as well as product launches is invaluable for advancing the company’s first-in-class tolerogenic drug candidate CUE-401 for autoimmune diseases, our partnered program CUE-501 and for securing strategic partners for our clinical-stage CUE-100 series assets.”
